News

Stocktwits on MSN9d
Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment
Regeneron Pharmaceuticals (REGN) shares dropped nearly 10% in premarket trading Friday after mixed results from late-stage ...
Clinical Trials Arena on MSN6d
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...
Pulmonology Advisor2d
Mixed Results for Itepekimab in Former Smokers With COPD
Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.
Fierce Biotech9d
Sanofi, Regeneron's IL-33 drug fails one of 2 COPD studies as FDA timeline thrown in doubt
Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...
Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure
Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after ...
Itepekimab Failure A Setback For Sanofi And Regeneron
Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...
Pharmabiz9d
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...